Test Catalog

Test ID: CDS1    
CNS Demyelinating Disease Evaluation, Serum

Useful For Suggests clinical disorders or settings where the test may be helpful

Diagnosis of inflammatory demyelinating diseases (IDDs) with similar phenotype to neuromyelitis optica spectrum disorder (NMOSD), including optic neuritis (single or bilateral) and transverse myelitis

 

Diagnosis of autoimmune myelin oligodendrocyte glycoprotein (MOG)-opathy

 

Diagnosis of neuromyelitis optica (NMO)

 

Distinguishing NMOSD, acute disseminated encephalomyelitis (ADEM), optic neuritis, and transverse myelitis from multiple sclerosis early in the course of disease

 

Diagnosis of ADEM

 

Prediction of a relapsing disease course

Highlights

Myelin oligodendrocyte glycoprotein (MOG)-IgG with an NMO spectrum disorder like phenotype is now recognized as a sensitive and specific diagnostic antibody biomarker of inflammatory demyelinating disorders (IDDs).

 

Approximately 80% of patients fulfilling 2006 Wingerchuk criteria for neuromyelitis optica are seropositive for aquaporin-4 (AQP4)-IgG. Of the remaining 20%, one-third harbor MOG-IgG. Seropositivity predicts a relapsing phenotype and warrants immunosuppressive therapy. Patients only rarely harbor both antibodies.

 

There is currently no biomarker specific for MS (multiple sclerosis). Patients seropositive for MOG-IgG are commonly misdiagnosed as MS. Detection of MOG-IgG implies an inflammatory demyelinating disorder distinct from MS. MS therapies may worsen MOG-IgG associated IDDs, so correct diagnosis is important.

 

Seropositivity for MOG-IgG, in NMOSD like disorders, including optic neuritis (OT), transverse myelitis (TM), and acute disseminated encephalomyelitis (ADEM), predicts relapse and warrants consideration for maintenance immunosuppression.

 

Seropositivity for MOG-IgG in the setting of a severe relapse of central nervous system (CNS) demyelination warrants aggressive therapy with intravenous methylprednisolone or plasmapheresis.

Profile Information A profile is a group of laboratory tests that are ordered and performed together under a single Mayo Test ID. Profile information lists the test performed, inclusive of the test fee, when a profile is ordered and includes reporting names and individual availability.

Test IDReporting NameAvailable SeparatelyAlways Performed
CSI1CNS Demyelinating Disease Interp, SNoYes
NMOFSNMO/AQP4 FACS, SYesYes
MOGFSMOG FACS, SYesYes

Reflex Tests Lists tests that may or may not be performed, at an additional charge, depending on the result and interpretation of the initial tests.

Test IDReporting NameAvailable SeparatelyAlways Performed
NMOTSNMO/AQP4 FACS Titer, SNoNo
MOGTSMOG FACS Titer, SNoNo

Testing Algorithm Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

When the results of this assay require further evaluation of myelin oligodendrocyte glycoprotein (MOG-IgG1), the MOG-IgG1 titer will be performed at an additional charge.

 

When the results of this assay require further evaluation of neuromyelitis optica (NMO)/Aquaporin-4-IgG, the neuromyelitis optica (NMO)/aquaporin-4-IgG titer will be performed at an additional charge.

 

See CNS Demylenating Evaluation Algorithm-Serum in Special Instructions.

Special Instructions Library of PDFs including pertinent information and forms related to the test

Method Name A short description of the method used to perform the test

Flow Cytometry

NY State Available Indicates the status of NY State approval and if the test is orderable for NY State clients.

Yes

Reporting Name Lists a shorter or abbreviated version of the Published Name for a test

CNS Demyelinating Disease Eval, S

Aliases Lists additional common names for a test, as an aid in searching

ADEM
AQP4
Aquaporin
Devic's Antibody
NMO (Neruomyelitis Optica)
NMO-IgG
Optic Neuritis Antibody
Transverse Myelitis Antibody
Vision Loss Antibody